Is this you? Create Your Porfile
Avatar

Mei Wang

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Mei Wang is active.

Explore More

Publication

Featured researches published by Mei Wang.

Journal of Clinical Oncology | 2018

Development of non-hematological adverse events in apatinib-treated gastric cancer and their association with clinical outcome: Results from a phase IV study.

Yi Ba; Jin Li; Shukui Qin; Lu Wen; Wenying Deng; Guifang Zhang; Tongfu Jia; Haijun Zhong; Jianwei Yang; Xiaoyan Lin; Yuxian Bai; Yifu He; Zhong Xie; Tienan Yi; Xiang-yuan Wu; Feng Ye; Likun Liu; Yong Huang; Mei Wang; Junsheng Wang

Journal of Clinical Oncology | 2018

BMI differences for clinical outcome in patients with advanced or metastatic gastric cancer treated with apatinib: Data from a post-marketing phase IV study (Ahead-G201).

Yuxian Bai; Shukui Qin; Jin Li; Lu Wen; Junsheng Wang; Wenying Deng; Guifang Zhang; Tongfu Jia; Yi Ba; Jianwei Yang; Xiaoyan Lin; Yifu He; Zhong Xie; Tienan Yi; Xiang-yuan Wu; Feng Ye; Likun Liu; Yong Huang; Mei Wang; Haijun Zhong

Journal of Clinical Oncology | 2018

Impact of time to progression on first-line therapy on clinical outcomes in advanced gastric cancer treated with apatinib: data from a phase IV study (Ahead-G201).

Zhong Xie; Shukui Qin; Jin Li; Lu Wen; Junsheng Wang; Wenying Deng; Guifang Zhang; Tongfu Jia; Yi Ba; Haijun Zhong; Jianwei Yang; Xiaoyan Lin; Yuxian Bai; Yifu He; Tienan Yi; Xiang-yuan Wu; Feng Ye; Likun Liu; Mei Wang; Yong Huang

Journal of Clinical Oncology | 2018

Clinical benefit of continuing apatinib beyond progression in advanced or metastatic gastric cancer.

Shukui Qin; Lu Wen; Junsheng Wang; Wenying Deng; Guifang Zhang; Tongfu Jia; Yi Ba; Haijun Zhong; Jianwei Yang; Xiaoyan Lin; Yuxian Bai; Yifu He; Zhong Xie; Tienan Yi; Xiang-yuan Wu; Feng Ye; Likun Liu; Yong Huang; Mei Wang; Jin Li

Journal of Clinical Oncology | 2018

Response to apatinib by the number of metastatic organs in patients with advanced or metastatic gastric cancer: Subgroup analysis from a phase IV study (Ahead-G201).

Yifu He; Jin Li; Shukui Qin; Lu Wen; Junsheng Wang; Wenying Deng; Guifang Zhang; Tongfu Jia; Yi Ba; Haijun Zhong; Jianwei Yang; Xiaoyan Lin; Yuxian Bai; Zhong Xie; Tienan Yi; Xiang-yuan Wu; Feng Ye; Yong Huang; Mei Wang; Likun Liu

Journal of Clinical Oncology | 2018

Effect of ECOG PS on outcome of advanced or metastatic gastric patients treated with apatinib: Analysis from a post-marketing phase IV study.

Xiaoyan Lin; Jin Li; Shukui Qin; Lu Wen; Junsheng Wang; Wenying Deng; Tongfu Jia; Yi Ba; Haijun Zhong; Jianwei Yang; Yuxian Bai; Yifu He; Zhong Xie; Tienan Yi; Xiang-yuan Wu; Feng Ye; Likun Liu; Yong Huang; Mei Wang; Guifang Zhang

Journal of Clinical Oncology | 2018

Safety of apatinib as third-line or beyond treatment in advanced or metastatic gastric cancer: Results from a multicenter phase IV study (Ahead-G201).

Jin Li; Lu Wen; Junsheng Wang; Wenying Deng; Guifang Zhang; Tongfu Jia; Yi Ba; Haijun Zhong; Jianwei Yang; Xiaoyan Lin; Yuxian Bai; Yifu He; Zhong Xie; Tienan Yi; Xiang-yuan Wu; Feng Ye; Likun Liu; Yong Huang; Mei Wang; Shukui Qin

Journal of Clinical Oncology | 2018

Does hypertension history in patients with advanced gastric cancer has an impact on clinical outcomes following apatinib treatment? A subgroup analysis based on data from Ahead-G201 study.

Tienan Yi; Jin Li; Shukui Qin; Lu Wen; Junsheng Wang; Wenying Deng; Guifang Zhang; Tongfu Jia; Yi Ba; Haijun Zhong; Jianwei Yang; Xiaoyan Lin; Yuxian Bai; Yifu He; Zhong Xie; Xiang-yuan Wu; Feng Ye; Likun Liu; Yong Huang; Mei Wang

Journal of Clinical Oncology | 2018

Association of proteinuria, hypertension, and hand-foot-skin reaction with efficacy of apatinib in gastric cancer: Results from the post-marketing study (Ahead-G201).

Jin Li; Wenying Deng; Lu Wen; Junsheng Wang; Guifang Zhang; Haijun Zhong; Tongfu Jia; Jianwei Yang; Yi Ba; Yuxian Bai; Xiaoyan Lin; Mei Wang; Lin Wang; Likun Liu; Yifu He; Min Tao; Congying Xie; Feng Ye; Xiang-yuan Wu; Shukui Qin

Journal of Clinical Oncology | 2018

Initial dose of apatinib in Chinese patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction in third- or later-line setting: 500 mg or 850 mg?

Wenying Deng; Shukui Qin; Jin Li; Lu Wen; Junsheng Wang; Guifang Zhang; Haijun Zhong; Jianwei Yang; Yi Ba; Yuxian Bai; Xiaoyan Lin; Mei Wang; Lin Wang; Likun Liu; Yifu He; Min Tao; Congying Xie; Feng Ye; Xiang-yuan Wu; Tongfu Jia

Explore More

Collaboration

Dive into the Mei Wang's collaboration.

Top Co-Authors
Avatar

Feng Ye

Xiamen University

View shared research outputs
Top Co-Authors
Avatar

Jin Li

Fudan University

View shared research outputs
Top Co-Authors
Avatar

Shukui Qin

Huazhong University of Science and Technology

View shared research outputs
Top Co-Authors
Avatar

Xiang-yuan Wu

Sun Yat-sen University

View shared research outputs
Top Co-Authors
Avatar

Xiaoyan Lin

Fujian Medical University

View shared research outputs
Top Co-Authors
Avatar

Yi Ba

Tianjin Medical University Cancer Institute and Hospital

View shared research outputs
Top Co-Authors
Avatar

Yuxian Bai

Harbin Medical University

View shared research outputs
Top Co-Authors
Avatar

Lin Wang

Peking Union Medical College

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge